Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products


Posted January 27, 2021 by kevinKD123-123_123

In order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives
 
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Type of Product
 API
 FDF

 Type of Expression System Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Size of Manufacturer
 Small
 Mid-sized
 Large / Very Large

 Type of Biologic
 Antibody
 Vaccine
 Others

The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
 ChemPartner Biologics
 JHL Biotech
 JOINN Biologics
 MabPlex
 Mycenax Biotech
 WuXi AppTec

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Case Study: Comparison of Small Molecules and Large Molecules

5. Competitive Landscape

6. Company Profiles

7. Partnerships

8. Recent Expansions

9. Clinical Trial Analysis

10. Regional Capability Analysis

11. Capacity Analysis

12. Big Pharma Biopharmaceutical Manufacturing Initiatives in China

13. Make Versus Buy Decision Making Framework

14. Market Sizing and Opportunity Analysis

15. COVID-19 Impact on China Biopharmaceutical CMO Market

16. SWOT Analysis

17. Future of the China Biopharmaceutical CMO Market

18. Interview Transcripts

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Roots Analysis
Country American Samoa
Categories Biotech , Health , Industry
Tags healthcare , pharmaceutical , wellness and fitness
Last Updated January 27, 2021